β-elemene inhibits the proliferation of T24 bladder carcinoma cells through upregulation of the expression of Smad4

XINSHENG LU¹, YI WANG², HONGMEI LUO³, WEIBIN QIU¹, HU HAN¹, XIAN CHEN² and LUOYAN YANG¹

¹Department of Urology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011; ²Department of Urology, Second Affiliated Hospital of University of South China; ³Department of Histology and Embryology, University of South China, Hengyang, Hunan 421001, P.R. China

Received July 6, 2012; Accepted November 5, 2012
DOI: 10.3892/mmr.2012.1206

Abstract. β-elemene, a non-cytotoxic antitumor reagent, inhibits the growth, proliferation and DNA synthesis of multiple types of malignant cells, resulting in the apoptosis or suppressed vascularization of tumors. β-elemene is also able to enhance the immunogeneity of the tumor cells and ameliorate systematic cellular immunity in the tumor-bearing body. Moreover, β-elemene has the advantages of high efficiency, safety and low possibility of drug tolerance over other antitumor agents used in antitumor treatment. Therefore, β-elemene has great potential in clinical applications. However, the mechanism of β-elemene antitumor activity is largely unknown. The aim of this study was to investigate whether β-elemene is able to repress the proliferation of T24 bladder carcinoma cells through regulation of the expression of the tumor suppressor gene, Smad4. Results of a methylthiazolyl tetrazolium (MTT) assay indicated that the proliferation of T24 cells was repressed by β-elemene in a time- and concentration-dependent manner. The lowest concentration of β-elemene to inhibit cell survival by >50% was determined using IC₅₀ software. Microscopic observation also demonstrated the potential of β-elemene to induce the apoptosis of cancer cells. Western blot and RT-PCR analyses revealed that the expression of the Smad4 protein and mRNA was upregulated by treatment with β-elemene. Our results revealed that β-elemene was able to upregulate the expression of Smad4 in tumor cells to inhibit the proliferation of these cells.

Introduction

Elemene is an effective antitumor agent extracted from Curcuma aromatica Salisb. of the Zingiberaceae plant family, which is used as a national class II noncytotoxic antitumor agent in China. The main ingredient of elemene is 1-methyl-1-ethylene-2,4-diisopropyl cyclohexane (C15H24), which is also known as β-elemene. α- and γ-elemene, as well as other terpene compounds, are also components of elemene, and all are effective antitumor agents. β-elemene has been investigated in numerous studies and has demonstrated potent ability to inhibit the growth of and kill multiple types of malignant cells in vitro and in vivo (1,2). Therefore, β-elemene is intensely investigated as an antitumor agent at present. TGF-β signaling pathways are able to regulate numerous cellular processes, including growth, development, division, death, oncogenesis and tumor progression, and Smad proteins are involved in these processes (3,4) Smad proteins participate in the signal transduction of the TGF family directly in the form of adjuvant activators downstream of the TGF-β ligand (5-7). Smad4 was first identified by Lagna in 1996 and was recognized as a candidate tumor suppressor gene (8). Smad4 plays a role in Smad-mediated signal transduction as the co-mediator of all Smads (9).

Our study found that β-elemene effectively inhibited the proliferation of T24 cells in a concentration- and time-dependent manner, and induced the apoptosis of T24 cells by upregulating the expression of the Smad4 gene, which provided a theoretical basis for the use of β-elemene in the treatment of bladder cancer.

Materials and methods

Reagents. β-elemene was purchased from Jin Gang Pharmaceutical Co. (Dalian, China). Trypsin was purchased from Bi Yuntian (Haimen, China). Dimethyl sulfoxide (DMSO) was purchased from Sheng Gong Biological Engineering Co. (Shanghai, China). Methylthiazolyl tetrazolium (MTT) was purchased from Sigma (St. Louis, MO, USA). Agents for primer synthesis, DEPC, ethidium bromide and RNase-free water were purchased from Sheng Gong Biological Engineering Co.

Cell culture. The bladder cancer cell line T24 was purchased from the cell repository of Xiangya Medical College of Zhongnan University. The cells were cultured in RPMI-1640 medium (Gibco, Carlsbad, CA, USA) with 10% fetal calf serum (Sijiqing Co., Hangzhou, China) at 37°C with 5% CO₂ and 95% humidity.

Correspondence to: Professor Luoyan Yang, Department of Urology, The Second Xiangya Hospital of Central South University, No. 139 Renmin Zhong Road, Changsha, Hunan 410011, P.R. China E-mail: luoyany@yahoo.com

Key words: β-elemene, Smad4, human bladder cancer
**MTT assay.** T24 cells in the exponential growth phase were inoculated into a 96-well plate, with 10^3-10^4 cells and 200 µl medium in each well. After 24 h of culturing, 0, 0.004, 0.008, 0.01, 0.02, 0.04, 0.06 or 0.08 mg/ml of β-elemene was added to the culture. The cells were cultured for a further 24, 48 or 72 h, and the absorbance at 570 nm (OD_{570}) of each well was detected using an enzyme-linked immunoassay apparatus (model DG3022, Fourth Military Medical University and the state-owned East Electronic Tube Factory, China). Each concentration of β-elemene was used to treat the cells in four wells, and the OD_{570} of untreated cells was normalized as 0.

The survival rate of the T24 cells was calculated by dividing the OD_{570} value of the experimental group by that of the control group. IC_{50} (independently researched and developed by our own laboratory) was used to calculate the concentration of β-elemene for each treatment time that would inhibit cell growth by 50%.

**Microscopic observation.** T24 bladder carcinoma cells in the exponential growth phase were digested and inoculated into six-well plates with 5x10^3 cells per well. The cells were combined with 2 ml substrate in each well and kept in an incubator at 37°C with 5% CO₂ and saturated humidity for 24 h. After the cells in each well had become adherent, they were separated into two groups. The control group was untreated and the test group was incubated with 0.02 mg/ml β-elemene until cell survival was inhibited by ≥50%. The cells were incubated for a further 24, 48 or 72 h and then subjected to observation under an inverted microscope.

**RT-PCR.** Total RNA was extracted using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) from the control cells and the cells treated with 0.02 mg/ml β-elemene for 24, 48 or 72 h. For each sample, the ratio OD_{260}/OD_{280} was 1.70-1.95 by ultraviolet spectrophotometric analysis and the purity of the RNA was determined by electrophoresis. cDNAs were obtained using an AMV reverse transcriptional kit (Promega Corporation, Madison, WI, USA) according to the manufacturer’s instructions. The mRNA levels of Smad4 were analyzed by PCR, and 5 µl of the PCR product was separated using 2% agarose gel containing 0.5 mg/ml ethidium bromide. The expression of β-actin mRNA was detected as an internal control. Images of the gel were captured with an EC3 System gel image analyzer (UVP, Upland, CA, USA). Each experiment was repeated at least 3 times.

**Western blot.** Untreated cells and cells that had been treated with 0.02 mg/ml β-elemene for 24, 48 or 72 h to reach ≥50% inhibition of cell survival were collected. The total protein was extracted and then quantified by the BCA method (Pierce Biotechnology, Inc. Rockford, IL, USA). An equal amount of protein was subjected to 6% SDS-PAGE. After electrophoretic separation, the proteins were transferred onto a polyvinylidene fluoride (PVDF) membrane (Bi Yuntian). The membrane was then incubated with Smad4 monoclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and β-actin monoclonal antibody (Zhongshan Jinqiao, Beijing, China). After incubating with anti-mouse or anti-rabbit secondary antibodies (Santa Cruz Biotechnology, Inc.) and rinsing with buffer solution (Bi Yuntian), the protein bands were developed by chromogenesis with a DAB luminescence kit (Bi Yuntian). The signals of the bands were digitally scanned and quantified by gray scale scanning, and were analyzed to determine the gray scale (Value V) of every product using Alpha Imager 2200 software (Alpha Innotech Corp., San Leandro, CA, USA). The relative expression levels of protein from each sample were calculated by dividing Value V of the target protein by that of the corresponding β-actin.

**Statistical analysis.** Data are presented as the mean ± standard deviation (SD). Variance analysis was performed using one-way analysis of variance (ANOVA) with SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). The LSD t-test was performed for the comparison of means between the treatment and control groups, and the SNK-q test was used for the comparison of means between the treatment groups. P<0.05 was considered to indicate a statistically significant result.

**Results**

β-elemene decreased the survival rate of T24 cells. To determine the survival rate of the T24 bladder carcinoma cells following treatment with various concentrations of β-elemene for different times, the OD_{570} values of the cells following treatment with 0.004, 0.008, 0.01, 0.02, 0.04, 0.06 or 0.08 mg/ml of β-elemene for 24, 48 and 72 h were measured by MTT assay. The results revealed that the survival rates of the T24 cells treated with <0.02 mg/ml β-elemene for 24, 48 or 72 h were >60, 45 and 30%, respectively, while the survival rates of the cells treated with >0.02 mg/ml β-elemene were <30, 25 and 23% respectively (Fig. 1A). Therefore, the cell survival rate was inversely correlated with the concentration of β-elemene. One-way ANOVA showed that the P-values between the groups of cells treated with different concentrations of β-elemene for 24, 48 and 72 h were 0.065, 0.820 and 0.117, respectively, all of which were >0.05, indicating the general homogeneity of variance in OD values between different groups and the control (a total of 8 groups). Moreover, when the cells were treated with β-elemene for 24 and 48 h, significant differences were observed in the OD values between any two groups treated with different concentrations of β-elemene or the control group (P<0.05). However, when the cells were treated for 72 h, there were a few exceptions. For example, the P-value for the comparison of ODs between the 0.02 and 0.04 mg/ml treatment groups was 0.07, between the 0.01 and 0.02 mg/ml treatment groups was 0.294, and between the 0.008 and 0.01 mg/ml treatment groups was 0.17. Therefore, the cell survival rate was inversely correlated with the concentration of β-elemene used to treat the cells.

By analyzing the OD values of cells treated with the same concentration of β-elemene for different time periods, we found that the differences in the OD values in different time periods between any two groups were also statistically significant (P<0.05). The OD_{570} values of the cells decreased as the treatment time with β-elemene increased, suggesting that the survival rate of the T24 cells was also inversely correlated with the incubation time. The IC_{50} values of the T24 cells treated with β-elemene were calculated by IC_{50} software that we independently developed in our own laboratory, and the IC_{50} values for 24, 48 and 72 h treatment were 0.015, 0.010 and
According to the above analysis, the lowest concentration of β-elemene that inhibited cell survival by >50% for different treatment times, i.e., 0.02 mg/ml for 24 h, was chosen for following studies.

β-elemene treatment markedly changed the morphology of T24 cells. We investigated the morphology of the T24 cells following β-elemene treatment. Adhesion of the majority of the cells was observed under an inverted microscope at 12 h post-passage. The cells extended and enlarged to form spindles, triangles, fibrous shuttles or polygons, with an oval nucleus in the center containing 2-5 nucleoli (Fig. 2A). These cells grew well, appeared homogenous under the optical microscope and were highly transparent. The untreated cells proliferated rapidly and multiplied markedly within 24 h to enter the logarithm growth period. However, the cells treated with 0.02 mg/ml β-elemene for 24 h showed a tendency for suspended growth with a decreased rate of attachment, and some of the cells became round, elliptical or irregular in shape (Fig. 2B and C). Cells treated for 48 h showed increased percentages of round cells, with some cells germinated along the cellular surface, decreased in size with condensed cytoplasm and a clearly decreased cytoplasm to nucleus ratio, which indicated that the process of apoptosis had been initiated. Moreover, the percentages of suspended or raised single-layer cells increased and some cells collapsed into fragments (Fig. 2D and E). When the cells were incubated with 0.02 mg/ml β-elemene for 72 h, most of the cells lost their normal morphology, and numerous suspended cells appeared, with fragments in the cellular membrane and condensed nucleolus (Fig. 2F and G). These results indicated that the morphology of the T24 cells changed as the duration time of the β-elemene treatment varied. In summary, when the incubation time increased, the cells were more likely to become round or elliptical, followed by nuclear condensation, cellular germination, appearance of apoptotic bodies, and eventually the rupture of the cell membrane, cell suspension and fragmentation.
β-elemene treatment upregulated Smad4 gene expression in T24 cells. We next sought to investigate how β-elemene functions in decreasing T24 cell survival. The expression of Smad4 mRNA in untreated and β-elemene-treated T24 cells was detected by RT-PCR. The purity of the extracted mRNA was verified by agarose gel separation (Fig. 3). The expression levels of Smad4 mRNA increased gradually after 24, 48 and 72 h of treatment with 0.02 mg/ml β-elemene (P<0.001; Fig. 4A). The increase in Smad4 mRNA expression levels was significant in the treated T24 cells at each time-point compared with that in the untreated cells (LSD t-test, P<0.01). Moreover, the expression levels of Smad4 mRNA in the T24 cells treated with 0.02 mg/ml β-elemene were statistically significantly different between any two incubation time-points (SNK-q test, P<0.01). These findings suggest that 0.02 mg/ml β-elemene upregulated the expression of Smad4 mRNA in the T24 bladder carcinoma cells significantly, and that the upregulation of Smad4 mRNA expression correlated positively with the incubation time.

Moreover, the expression of Smad4 protein in the T24 cells was detected by western blot analysis. The Smad4 protein was also upregulated in the T24 cells incubated with 0.02 mg/ml β-elemene for 24, 48 and 72 h. (F_{time}=249.89, P<0.001, Fig. 4B). Significant differences in protein expression levels were found at each time-point in cells treated with β-elemene compared with the control cells (LSD t-test, P<0.01). The differences in protein expression levels were also statistically significant between any two treated groups of cells (24, 48 or 72 h, SNK-q test, P<0.05). These findings indicate that 0.02 mg/ml β-elemene upregulated the expression of Smad4 protein in T24 bladder carcinoma cells in a time-dependent manner. Therefore, we suspect that β-elemene may decrease the survival of T24 cells by upregulating the expression of the tumor suppressor gene Smad4.

Discussion

β-elemene is an active element extracted from *Curcuma aromatica* Salisb., a natural herb of the family Zingiberaceae. Due to of its strong effect in inhibiting tumor growth and proliferation, β-elemene is used in the treatment of lung cancer, malignancies of the alimentary tract and brain tumors, and an emulsion form of β-elemene has been designated as a class II noncytotoxic antitumor agent in China (10-12). A number of studies of the antitumor mechanism of β-elemene have been carried out during recent years, mainly concerning its ability to inhibit tumor vascularization, repair DNA damage and act as a sensitizer for radiotherapy (13-15). Since β-elemene is able to suppress the development of tumors significantly by inhibiting proliferation and inducing apoptosis (16,17), previous studies concerning β-elemene have focused on its relationship with oncogenes, not on its relationship with tumor suppressor genes. Our study aimed to investigate the antitumor mechanism of β-elemene by monitoring the expression of a well-known tumor suppressor gene, Smad4, in β-elemene-treated T24 bladder carcinoma cells.

At present, the role of Smad4 in oncogenesis is of interest to numerous researchers. The antitumor effect of Smad4 depends on its potential to mediate the growth inhibition induced by TGF-β (18). TGF-β is able to inhibit the growth of epidermal cells, induce differentiation and maintain hereditary stability. The overexpression of TGF-β in tumor cells may affect the tumor cells and their matrix, thereby inducing infiltration and metastasis and interfering with antitumor immunity (19,20).

Uncontrolled cell proliferation is the prerequisite of oncogenesis. Therefore, studies concerning tumor proliferation kinetics have been considered as the best approach for screening antitumor drugs or exploring their effects, since they may aid the understanding of the proliferation and metabolism of malignancies and elucidation of the mechanisms through which antitumor agents or physical/chemical factors act upon tumor cells. A number of studies have revealed the significant inhibition of tumor growth by β-elemene. A study carried out by Zhu *et al* (21) demonstrated that β-elemene inhibited the proliferation of the neuroblastoma cell line U87 and increased its sensitivity to cisplatin through activation of the GMF-β pathway and inhibition of the phosphorylation of MKK3/6. It
has also been reported by Chen et al (22) that β-elemene inhibited the growth and metastasis of melanoma by inhibiting the vascularization induced by vascular endothelial growth factor (VEGF). Another study by Zhu et al (23) revealed the effect of β-elemene in blocking the U87 glioma cell line at G0/G1 through its upregulation of P-MKK3 and P-MKK6 levels. Using an MTT assay, Li et al (16,24) demonstrated the ability of β-elemene to repress the proliferation of the prostate cancer cell lines DU145 and PC-3, both of which are insensitive to androgen, and to improve the inhibitory effect of cisplatin in a time- and dose-dependent manner in the human non-small cell lung cancer (NSCLC) cell lines H460 and A549.

Our study evaluated the cytotoxic effects of β-elemene on T24 human bladder carcinoma cells by MTT assay, and revealed that the survival rate of the T24 cells decreased as the treatment duration and concentration of β-elemene increased, indicating that β-elemene inhibited the growth of the T24 cells in a time- and concentration-dependent manner. These results were in accordance with previous studies of other malignancies. The IC_{50} values of β-elemene in the T24 cells treated for 24, 48 and 72 h were calculated by SPSS software to be 0.015, 0.010 and 0.006 mg/ml, respectively. A higher IC_{50} value for 24 than 48 h suggests that a low concentration β-elemene treatment may achieve the same inhibitory effect as a high concentration treatment if the incubation time is long enough. Our results indicate that the inhibition of the growth and proliferation of T24 human bladder carcinoma cells by β-elemene may be one of the key mechanisms against cancer.

In our study, after treatment with 0.02 mg/ml β-elemene for 24 to 72 h, the T24 cells appeared to be suspended when subjected to microscopic observation. Some cells became round, elliptical or irregular in shape, with weakened light refraction and attachment ability. Those cells had a tendency for suspended growth, and a few became round and detached from the well. Some cells even collapsed into fragments and apoptotic bodies were observed along the surface of cell membrane after 48 h of treatment. These findings further support the ability of β-elemene to induce the apoptosis of bladder cancer cells.

The development of tumors is complicated, involving multiple genes, procedures and stages. Abnormality in apoptosis correlates closely with oncogenesis, tumor development and metastasis. β-elemene has the ability to kill malignant cells and inhibit the growth of neoplasms. Liu et al (25) found that β-elemene induced the apoptosis of A49 human NSCLC cells by inhibiting the activity of the PI3K/Akt/mTOR/p70S6K pathway. Li et al (26) revealed that β-elemene induced apoptosis in A549 human NSCLC cells in a time- and dose-dependent manner. A study by Ying et al (27) indicated that β-elemene may induce the apoptosis of HL-60 human leukemia cells by releasing cytochrome c and other apoptosis inducers to the cytoplasm as well as by translocating Bax from the cytoplasm to mitochondria, and this induction appeared to be time-dependent. However, the mechanism by which β-elemene inhibits tumors is not fully clear.

Furthermore, the expression levels of the Smad4 gene were upregulated by 0.02 mg/ml β-elemene in a time-dependent manner. The expression levels of Smad4 following 24, 48 and 72 h of treatment were analyzed by RT-PCR and western blot analysis, and the results revealed the elevated levels of mRNA and protein. Since the upregulation of expression was correlated closely with the time of β-elemene treatment, it is speculated that expression of Smad4 also correlated with the concentration of β-elemene, which requires further investigation. These findings suggest that Smad4 functions by regulating the proliferation of bladder cancer cells, which results in the repression of proliferation and the induction of apoptosis.

In conclusion, we found that β-elemene inhibits the growth and proliferation of bladder cancer cells significantly, in a time- and concentration-dependent manner. Microscopic observation also revealed the potential of β-elemene to induce the apoptosis of cancer cells. Moreover, β-elemene was able to increase the expression levels of Smad4, a tumor suppressor gene, in T24 human bladder carcinoma cells, in a time-dependent manner. These results suggest that the upregulation of Smad4 gene expression may be one of the antitumor mechanisms of β-elemene and provide a theoretical basis for the treatment of bladder cancer. Further studies are required to elucidate the influence of β-elemene on other oncogenes, tumor suppressor genes and genes associated with apoptosis.

Acknowledgements

This study was supported by the Hunan Provincial Natural Scientific Research Fund (Grant Number, 2010851012154355).

References


